What happened
Shares of medical device manufacturer AngioDynamics (ANGO 0.52%) jumped 5.3% through 12:05 p.m. ET on Monday ahead of its expected earnings release next month. This morning, investment bank H.C. Wainwright initiated coverage of AngioDynamics stock with a buy rating.
So what
The company has a couple of key products: AlphaVac, a device for removing blood clots from veins; and NanoKnife, which uses electricity to destroy cancerous cells. With these and other tools, H.C. Wainwright says, AngioDynamics is a stock with the potential to "continue to grow at an annual rate around 20%," reports TheFly.com in coverage of Wainwright's report -- and that would help the stock nearly triple in price over the next 12 months to a target of $19.
But right now, AngioDynamics isn't growing anywhere near 20% annually. Last month, the company grew its revenue less than 5%, and was not profitable. Furthermore, according to data from S&P Global Market Intelligence, revenue growth has averaged something closer to 8.6% annually over the past three years. So if anything, the growth rate seems to be slowing down.
Now what
Although I have been rooting for this stock for years, AngioDynamics seems to be stuck in a rut and going nowhere fast -- certainly not 20% fast.
With no recent history of profits, and most analysts agreeing that AngioDynamics has no hope of becoming profitable before 2027 at the earliest, I fear this stock is one to avoid -- not buy.
